Tamboran Schedules Fourth Quarter and FY24 Earnings Release and Webcast
Tamboran Schedules Fourth Quarter and FY24 Earnings Release and Webcast
Tamboran Resources Corporation (NYSE: TBN, ASX: TBN)plans to release the Company’s fourth quarter earnings and operational update before NYSE market opens on Friday September 20, 2024.
Managing Director and Chief Executive Officer, Mr. Joel Riddle will host a webcast commencing at 8:00am ET to provide an update on the Company’s operations in the Beetaloo Basin. This will be followed by a short Q&A session with analysts.
Access to the live audio webcast for the conference call is available via Tamboran’s website at https://ir.tamboran.com/. A recording of the webcast will be available on the Tamboran Resources website following completion of the presentation.
Time: |
8:00am ET (New York) | 10:00pm AEST (Sydney, Melbourne) |
|
Date: |
Friday September 20, 2024 |
This announcement was approved and authorised for release by Joel Riddle, Managing Director and Chief Executive Officer of Tamboran Resources Corporation.
Investor enquiries:
Chris Morbey, Vice President – Investor Relations
+61 2 8330 6626
Investors@tamboran.com
Media enquiries:
+61 2 8330 6626
Media@tamboran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240911592528/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks